A manic episode in a 64-year-old man: An adverse effect of varenicline

General Hospital Psychiatry

Volumn 33, Issue 2, 2011, Pages 200.e9-200.e11

  Ahmed, Amir ^a  

^a Department of Elderly   (Netherlands)

Author keywords

Adverse drug reactions; Bipolar disorder; Mania; Neuropsychiatric symptoms; Smoking cessation; Varenicline

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; CITALOPRAM; HYDROCHLOROTHIAZIDE; LORAZEPAM; MEPIRODIPINE; MIANSERIN; OXAZEPAM; PERINDOPRIL; QUETIAPINE; ROSUVASTATIN; VARENICLINE;

ABNORMAL BEHAVIOR; ADULT; AGITATION; ANAMNESIS; APHASIA; ARTICLE; BIPOLAR DISORDER; CASE REPORT; DEPRESSION; EUPHORIA; HEMIPARESIS; HUMAN; HYPERTENSION; IMPULSIVENESS; MALE; MANIA; MEMORY DISORDER; MENTAL CONCENTRATION; MENTAL DETERIORATION; MOOD DISORDER; MOTOR DYSFUNCTION; RESTLESSNESS; SLEEP DISORDER; SMOKING CESSATION; SPEECH DISORDER; STROKE; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

EID: 79956108425     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2010.11.005     Document Type: Article

References (29)

1. Lasser K., Boyd J.W., Woolhandler S., et al. Smoking and mental illness: a population-based prevalence study. JAMA 2000, 284(20):2606-2610.
2. Haustein K.O., Haffner S., Woodcock B.G. A review of the pharmacological and psychopharmacological aspects of smoking and smoking cessation in psychiatric patients. Int J Clin Pharmacol Ther 2002, 40(9):404-418.
3. Kalman D., Morissette S.B., George T.P. Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict 2005, 14:106-123.
4. Naranjo C.A., Busto U., Sellers E.M., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30(2):239-245.
5. Mihalak K.B., Carroll F.I., Luetje C.W. Varenicline is a partial agonist atalpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 2006, 70:801-805.
6. Product name: Champix. http://www.cbg-meb.nl/CBG/en/human-medicines/geneesmiddeleninformatieban k/default.htm.
7. Jorenby D.E., Hays J.T., Rigotti N.A., et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006, 296:56-63.
8. Kessler R.C., McGonagle K.A., Zhao S., et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994, 51:8-19.
9. Kandel D.B., Huang F.Y., Davies M. Comorbidity between patterns of substance use dependence and psychiatric syndromes. Drug Alcohol Depend 2001, 64(2):233-241.
10. Pumariega A.J., Nelson R., Rotenberg L. Varenicline-induced mixed mood and psychotic episode in a patient with a past history of depression. CNS Spectr 2008, 13(6):511-514.
11. Alhatem F., Black J.E. Varenicline-induced mania in a bipolar patient. Clin Neuropharmacol 2009, 32(2):117-118.
12. Freedman R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry 2007, 164(8):1269.
13. Raidoo B.M., Kutscher E.C. Visual hallucinations associated with varenicline: a case report. J Med Case Reports 2009, 3:7560.
14. Ahmed A.I.A., van Mierlo P., Jansen P. Sleep disorders, nightmares, depression and anxiety in an elderly patient treated with low-dose metoprolol. Gen Hosp Psychiatry 2010, 32(6):646.e5-646.e7.
15. Olivier P., Bertrand L., Tubery M., et al. Hospitalizations because of adverse drug reactions in elderly patients admitted through the emergency department: a prospective survey. Drugs Aging 2009, 26(6):475-482.
16. Paperwalla K.N., Levin T.T., Weiner J., et al. Smoking and depression. Med Clin North Am 2004;88(6):1483-1494, x-xi.
17. Glassman A.H. Cigarette smoking: implications for psychiatric illness. Am J Psychiatry 1993, 150(4):546-553.
18. Tsoh J.Y., Humfleet G.L., Munoz R.F., et al. Development of major depression after treatment for smoking cessation. Am J Psychiatry 2000, 157(3):368-374.
19. Prochaska J.J., Hall S.M., Tsoh J.Y., et al. Treating tobacco dependence in clinically depressed smokers: effect of smoking cessation on mental health functioning. Am J Public Health 2008, 98(3):446-448.
20. Gunnell D., Irvine D., Wise L., et al. Varenicline and suicidal behavior: a cohort study based on data from the General Practice Research Database. BMJ 2009, b3805:339.
21. Diehl D.J., Gershon S. The role of dopamine in mood disorders. Compr Psychiatry 1992, 33(2):115-120.
22. Ahmed A.I.A., van der Heijden F.M.M.A., van den Berkmortel H., et al. A man who wanted to commit suicide by hanging himself: an adverse effect of ciprofloxacin. Gen Hosp Psychiatry 2010, [in press].
23. Berk M., Dodd S., Kauer-Sant'anna M., et al. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand Suppl 2007, 434:41-49.
24. Cousins D.A., Butts K., Young A.H. The role of dopamine in bipolar disorder. Bipolar Disord 2009, 11(8):787-806.
25. Benowitz N.L. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin Pharmacol Ther 2008, 83(4):531-541.
26. Benowitz N.L. Cigarette smoking and nicotine addiction. Med Clin North Am 1992, 76(2):415-437.
27. Rollema H., Chambers L.K., Coe J.W., et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007, 52(3):985-994.
28. Coe J.W., Brooks P.R., Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005, 48(10):3474-3477.
29. Amit A., Paul V., Nicolas S., et al. Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am J Psychiatry 2000, 157:1108-1114.